No abstract available.
Hemorrhage*

No abstract available.
Child* ; Humans ; Peak Expiratory Flow Rate*

There has been few papers regarding the pathologic changes of kidney induced by contrast media, especially in terms of iodine concentration or osmolarity. In order to evaluate histopathologic changes, a series of rat kidneys, after injection of iodinated contrast media, were examined. A total of 220 rats were divided into two groups: those given Urografin-60% by 6.3 ml/Kg(1840mg/6.3ml):those given Urografin-76% by 5ml/Kg(1850mg/5ml). (the same amount of iodine but at different iodine concentration). The kidneys were removed and microscopically examined on 1, 2, 3, 5, 7, 10th days, 2nd, 3rd, 4th, 6th and 12th weeks after injection of contrast media, respectively. The results were as follows: Renal pathologic changes induced by contrast media were congestion and ectatic change of the interstitial vessels, epithelial degeneration and necrosis of the collectiong ducts. Congestion of interstitial vessels and epithelial degeneration and necrosis of the collecting ducts were severe in the higher iodine concentration Urografin-76% group(2100 Osm/Kg H2O) than the Urografin-60% group(1500 Osm/Kg H2O). And above pathological changes persisted for 12weeks without significant interval changes. The authors conclude that the renal damage induced by ionic contrast media becomes more severe in higher concentrations or osmolarities in spite of the same amount of iodine and that the pathologic changes persisted until 12 weeks without improvement.
Animals ; Contrast Media ; Diatrizoate* ; Estrogens, Conjugated (USP) ; Iodine ; Kidney ; Necrosis ; Osmolar Concentration* ; Rats*

No abstract available.
Pulmonary Edema*

Although the ultrasonography has been regarded as a important procedure in the diagnosis of intraabdominalabscess, there were relatively few papers concerning the ultrasonographic findings of periappendiceal abscess.Nineteen cases of surgically proven periappendiceal abscess caused by perforated appendicitis were studied byultrasonography at the Kyung Hee University Hospital during last 34 months. The results were as follows; 1.Diagnostic accuracy of the real-time ultrasonography was 94.7%(18/19). There were only one false positive and onefalse negative. 2. The location of abscesses were ; periappendiceal 68.4%(13/19), pelvic 21.0%(4/19), subhepatic5.3%(1/19) and subphrenic 5.3%(1/19) in order of frequency. 3. Variable echo-patterns of abscesses wereencountered. But irregular, thick walled, posteriorly reinforcing, echo-free or mixed echo-patterns were mostcommon.
Abscess ; Appendicitis ; Diagnosis ; Ultrasonography

Acquired digital fibrokeratoma is a relatively unusual benign fibrous tumor that is usually found on the distal extremities. It is characterized by a solitary, flesh-colored, firm and hyperkeratotic projection with a surrounding collarette of raised skin at the base. We report a case of acquired digital fibrokeratoma resembling cutaneous horn in a 31-year-old male who showed a 0.5x0.5x2 cm, firm, hyperkeratotic protruded mass with secondary changes including crust and bleeding on the left 4th finger.
Adult ; Animals ; Extremities ; Fingers ; Hemorrhage ; Horns* ; Humans ; Male ; Skin

Dermatophytoses are often observed coexisting fungal infections. Trichophyton (T.) rubrum syndrome is defined as the following obligatory criteria. (A) Skin lesions at the following four sites: (1) feet; (2) hands; (3) nails; and (4) at least one lesion in another location than (1) (2) or (3), except for groins. (B) Positive microscopic findings of KOH preparations of skin scrapings in all four locations. (C) Identification of T. rubrum by culture at three of the four locations at least. Three cases of T. rubrum syndrome is reported in a 50-year-old woman, in a 73-year-old man, and in a 55-year-old man.
Aged ; Female ; Foot ; Groin ; Hand ; Humans ; Middle Aged ; Skin ; Tinea ; Trichophyton*

BACKGROUND: The angiotensin-converting enzyme inhibitors have been found to be safe and efficacious in the treatment of essential hypertension. Fosinopril is the first angiotensin-converting enzyme inhibitor from a new class of agents containing phosphorus. This drug is known to be metabolized to almost and equal extent by the hepatic and renal pathways. METHODS: This study was performed to investigate the efficacy and safety of oral fosinopril, a new class of phosporus-containing angiotensin converting enzyme inhibitor, on essential hypertension. A single daily dose of 10mg to 20mg fosinopril was administered in 21 hypertensive patients with diastolic blood pressure in the range of 95mmHg-115mmHg while off all other anti-hypertensive agents for 10 weeks. Blood pressure and heart rate were measured every 4 weeks. The complete blood count, blood chemistry by SMA-12, serum electrolytes and urinalysis were performed at 12th week of therapy. RESULTS: 1) Baseline systolic and diastolic blood pressures after 2 weeks of placebo at sitting position were 158.8+/-15.7 and 99.4+/-6.3mmHg respectively. There was a statistcally significant reduction of blood pressure after 4 week treatment of fosinopril which was maintained up to 12 weeks of follow-up(158.8+/-15.7-99.4+/-6.3mmHg vs 139.3+/-18.2/86.6+/-10.3mmHg, p<0.05). 2) The proportion of responders defined by diastolic blood pressures less than 90mmHg or decline more than 10mmHg at 4, 8 and 12 weeks after treatment with fosinopril were 90.5, 95.2, and 95.2% respectively. 3) THere were no significant changes in blood chemistry, serum electrolytes, hematologic findings and heart rate over the treatment period. 4) Three patients experienced severe non-productive cough that required to discontinue the medication. CONCLUSION: In patients with mild to moderate hypertension, once-daily fosinopril(10mg and 20mg) provided significant anti-hypertensive effects without serious side effects. The 10mg dose was effective in majority of patients and may be considered as a starting dose.
Angiotensin-Converting Enzyme Inhibitors ; Antihypertensive Agents ; Blood Cell Count ; Blood Pressure ; Chemistry ; Cough ; Electrolytes ; Fosinopril* ; Heart Rate ; Humans ; Hypertension ; Peptidyl-Dipeptidase A ; Phosphorus ; Urinalysis

BACKGROUND: Cicletanine bydrochloride is a newly developed anti-hypertensive agent. The presence of a furopyridine group characterizes its uncommon chemical structure as an antihypertensive molecule. This clinical trial was performed to confirm the efficacy and safety of cicletanine for the treatment of hypertension as a monotherapy. METHODS: In order to investigate the efficacy and safety of oral cicletanine, a now class of antihypertensive durgs, the furopyridines, on essential hypertension, a single daily dose of 50mg to 100mg cicletanine was administered in 46 hypertensive patients with diastolic blood pressure in the range of 95mmHg-115mmHg. The patients were asked to cut off other anti hypertensive agents for 10 weeks prior to this clinical trial. Blood pressure and heart rate were measured every 4 weeks. The complete blood count, blood chemistry done by SMA-12, serum electrolytes and urinalysis were performed at the 12th week of therapy. RESULTS: 1) Baseline blood pressures after 2 weeks of placebo at sitting and standing positions were 158.7+/-16.1/102.9+/-6.2 and 148.7+/-14.5/102.7+/-6.7mmHg, respectively. The overall slope which represents the tendency of blood pressure decline over the treatment period with cicletanine for all the patients in each position are as follows ; -0.726(SE : 0.150) for sitting systolic blood pressure(BP), -0.390(SE : 0.080) for sitting diastolic BP, -0.214(SE : 0.183) for standing systolic BP and -0.341(SE : 0.139) for standing diastolic BP. 2) The slope of sitting systolic BP line in cicletanine 100mg treated group was significantly stiffer than that of cicletanine 50mg treated group(-0.445 vs -1.021, p=0.0336). 3) There were no significant interval changes in heart rate over the treatment period. 4) There were no significant interval changes in blood chemistry, electrolytes, hematologic findings and urinalysis over the treatment period. 5) Several side effects were observed in six patients(epigastric discomfort in 4, easy fatigue and insomnia in one patient, respectively). CONCLUSION: Treatment with cicletanine was well-tolerated and the incidence of side effects was relatively low. Because of its unique anti-hypertensive mechanism and moderated antihypertensive effects, cicletanine may be well suited in the treatment of hypertension combined with other classes of antihypertensive agents.
Antihypertensive Agents ; Blood Cell Count ; Blood Pressure ; Chemistry ; Electrolytes ; Fatigue ; Heart Rate ; Humans ; Hypertension ; Incidence ; Sleep Initiation and Maintenance Disorders ; Urinalysis

PURPOSE: A composite of aluminum and vanadium (Ti-6Al-4V) is one of the most common compositions of titanium-based alloys. Unfortunately, vanadium has been found to cause adverse reactions. We evaluated the effects of vanadium containing titanium alloy (Ti-6Al-4V) on an osteoblast-like cell line (SaOS-2). MATERIALS AND METHODS: We studied the biologic and morphologic responses of SaOS-2 cell to Ti alloy with grit blasting and Ti coated Ti alloy with grit blasting. We performed energy-dispersive x-ray spectroscopy (EDS) and scanning electron microscopy (SEM) investigations and performed a cell proliferation assay, ALP activity, and cell migration assay of SaOS-2 cells. RESULTS: The morphologic assessment of cells through SEM showed that the two surfaces were covered with similar amounts of small slender osteoblast like cells. The amount of proliferation, ALP activity and the migration extent of SaOS-2 cells on the surfaces of each group were not statistically different. CONCLUSION: We used a grit-blasted Ti-coated Ti alloy, coated using electron beam deposition, and a grit-blasted Ti alloy to evaluate the toxicity of Ti-6Al-4V on SaOS-2 cell. Compared with pure titanium, the vanadium-containing Ti-alloy did not show an adverse effect on SaOS-2 cells.
Alloys ; Aluminum ; Cell Line ; Cell Migration Assays ; Cell Proliferation ; Electrons ; Microscopy, Electron, Scanning ; Osteoblasts ; Spectrum Analysis ; Titanium ; Vanadium